Photo of Motomi (Tomi) Mori, Ph.D., M.B.A.

Motomi (Tomi) Mori Ph.D., M.B.A.

  • (503) 418-1555
    • Professor OHSU-PSU School of Public Health
    • Walter & Cora Brownfield Professor of Cancer Biostatistics
    • OHSU Knight Cancer Institute School of Medicine
    • Medical Informatics and Clinical Epidemiology School of Medicine

Dr. Mori has 28 years of experience as a collaborative cancer biostatistician, starting with the Fred Hutchinson Cancer Research Center (1989-1991), Huntsman Cancer Institute at the University of Utah (1991-1999), and the Knight Cancer Institute (Knight) at the Oregon Health & Science University (1999-present). As the Director of the Knight Biostatistics Shared Resource, she has a long standing collaboration with investigators in the Translational Oncology Program and the Cancer Prevention and Control Program in the Knight Cancer Institute. She holds a position of Walter and Clora Brownfield Endowed Professor of Cancer Biostatistics in the Knight Cancer Institute, is an elected Fellow of the American Statistical Association, President of the Western North American Region of the International Biometric Society (IBS), served on the NCI Subcommittee A (Cancer Centers of the National Cancer Institute Initial Review Group (2006-2011) and was a faculty for the AACR/ASCO Methods in Clinical Research Workshop in Vail, Colorado (2015-2017).

Areas of interest

  • Biostatistics, cancer research, clinical trials, precision oncology, early detection research


  • Ph.D., Biostatistics, University of Iowa, Iowa City Iowa 1989
  • M.B.A., Healthcare Management, Oregon Health & Science University, Portland Oregon 2016

Honors and awards

  • 2010 Fellow, American Statistical Association
  • 2005 Outstanding Alumni Award, College of Public Health, University of Iowa

Memberships and associations

  • American Statistical Association
  • International Biometric Society
  • American Association for Cancer Research
  • American Association for the Advancement of Science
  • American Society of Clinical Oncology


  • "A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Previously Untreated Advanced or Metastatic Colorectal Cancer." American Journal of Clinical Oncology: Cancer Clinical Trials  In: , Vol. 41, No. 12, 01.12.2018, p. 1193-1198.
  • "IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin." Journal of Experimental Medicine  In: , Vol. 215, No. 12, 01.12.2018, p. 3057-3074.
  • "MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis." Diseases of the colon and rectum  In: , Vol. 61, No. 11, 01.11.2018, p. 1290-1296.
  • "Functional genomic landscape of acute myeloid leukaemia." Nature  In: , Vol. 562, No. 7728, 25.10.2018, p. 526-531.
  • "Dual inhibition of JAK1/2 kinases and BCL2 : a promising therapeutic strategy for acute myeloid leukemia." Leukemia  In: , Vol. 32, No. 9, 01.09.2018, p. 2025-2028.
  • "Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes." Leukemia  In: , 29.03.2018, p. 1-14.
  • "Perceptions of control and unrealistic optimism in early-phase cancer trials." Journal of Medical Ethics  In: , Vol. 44, No. 2, 01.02.2018, p. 121-127.
  • "Comprehensive definition of human immunodominant CD8 antigens in tuberculosis." npj Vaccines  In: , Vol. 2, No. 1, 8, 01.12.2017.
  • "Evaluation of safety in biomarker driven multiple agent phase IB trial."   Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, 2017. p. 53-64.
  • "Variations in Unrealistic Optimism between Acceptors and Decliners of Early Phase Cancer Trials." Journal of Empirical Research on Human Research Ethics  In: , Vol. 12, No. 4, 01.10.2017, p. 280-288.
  • "Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 114, No. 36, 05.09.2017, p. E7554-E7563.
  • "Assessing Community Cancer care after insurance ExpanSionS (ACCESS) study protocol." Contemporary Clinical Trials Communications  In: , Vol. 7, 01.09.2017, p. 136-140.
  • "Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis." Cell Reports  In: , Vol. 19, No. 1, 04.04.2017, p. 203-217.
  • "The rodent liver undergoes weaning-induced involution and supports breast cancer metastasis." Cancer Discovery  In: , Vol. 7, No. 2, 01.02.2017, p. 177-187.
  • "MicroRNA signatures of colonic polyps on screening and histology." Cancer Prevention Research  In: , Vol. 9, No. 12, 01.12.2016, p. 942-949.
  • "Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate : A Randomized Controlled Trial." Nutrition and Cancer  In: , Vol. 68, No. 8, 16.11.2016, p. 1309-1319.
  • "Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women." Experimental Hematology  In: , Vol. 44, No. 9, 01.09.2016, p. 857-865.e5.
  • "The Impact of unreaslistic optimism on informed consent in early-phase oncology trials." IRB Ethics and Human Research  In: , Vol. 38, No. 5, 01.09.2016, p. 1-7.
  • "Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins : A Cross-sectional Analysis." Clinical Infectious Diseases  In: , Vol. 62, No. 9, 01.05.2016, p. 1111-1118.
  • "Treatment and Survival of Small-bowel Adenocarcinoma in the United States : A Comparison with Colon Cancer." Diseases of the Colon and Rectum  In: , Vol. 59, No. 4, 01.04.2016, p. 306-315.
  • "A new statistical decision rule for single-arm phase II oncology trials." Statistical Methods in Medical Research  In: , Vol. 25, No. 1, 01.02.2016, p. 118-132.
  • "Dispositional optimism and therapeutic expectations in early-phase oncology trials." Cancer  In: , 2016.
  • "Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care." Psycho-Oncology  In: , 2016.
  • "Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy." Cancer Prevention Research  In: , Vol. 8, No. 12, 01.12.2015, p. 1184-1191.
  • "Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes." Leukemia  In: , 25.06.2015.
  • "A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer." Investigational New Drugs  In: , Vol. 33, No. 2, 01.04.2015, p. 480-489.
  • "The association of type and number of chronic diseases with breast, cervical, and colorectal cancer screening." Journal of the American Board of Family Medicine  In: , Vol. 27, No. 5, 01.09.2014, p. 669-681.
  • "Improving colorectal cancer screening in Asian Americans : Results of a randomized intervention study." Cancer  In: , Vol. 120, No. 11, 01.06.2014, p. 1702-1712.
  • "Differential expression of microRNA-320a, -145, and -192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum." American Journal of Surgery  In: , Vol. 207, No. 5, 2014, p. 717-722.
  • "Assisted movement with proprioceptive stimulation reduces impairment and restores function in incomplete spinal cord injury." Archives of Physical Medicine and Rehabilitation  In: , Vol. 95, No. 8, 2014, p. 1447-1453.

Additional information

Edit profile